TMS for Depression: From Clinical Trials to Results
In this episode, we explore the evidence behind Transcranial Magnetic Stimulation (TMS) for depression, from early clinical trials to real-world effectiveness. What makes some patients respond better to TMS than others? We discuss response rates, treatment protocols, and the exciting development of faster treatment options. Faculty: Simon Kung, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 1 CME: TMS in Psychiatry: Innovations and Best Practices Exploring the Evidence of TMS for Depression
--------
16:27
A Guide to Selecting TMS Candidates
In this episode, we explore the crucial aspects of patient selection for Transcranial Magnetic Stimulation (TMS) in treating depression. We discuss insurance criteria, contraindications, and practical considerations. Did you know that while TMS was FDA-approved in 2008, it wasn't widely accessible until Medicare began covering it in 2014? Faculty: Simon Kung, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 1 CME: TMS in Psychiatry: Innovations and Best Practices Optimizing Patient Selection for TMS Treatment
--------
13:35
Rethinking Clozapine Monitoring: 22 Years of Data
In this episode, we explore a landmark Finnish study examining the long-term risk of agranulocytosis in patients taking clozapine. The research followed 62,000 patients over 22 years, providing crucial data about this rare but serious side effect. Could these findings change how we approach clozapine prescribing and monitoring requirements? Faculty: Oliver Freudenreich, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.75 CME: Quick Take Vol. 66 Does Clozapine's Agranulocytosis Risk Persist Beyond Initial Treatment Period?
--------
13:07
Understanding TMS in OCD: Evidence and Practice
In this episode, we explore Transcranial Magnetic Stimulation (TMS) as a treatment option for Obsessive-Compulsive Disorder (OCD). We discuss the FDA-approved devices, unique protocols, and why patients need their anxiety triggered before each session. Did you know TMS for OCD targets a completely different brain region than TMS for depression? Faculty: Simon Kung, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 1 CME: TMS in Psychiatry: Innovations and Best Practices Exploring the Evidence of TMS for OCD
--------
8:32
Breaking Down the TRAILBLAZER-ALZ 2 Trial
In this episode, we explore donanemab, a groundbreaking monoclonal antibody treatment for Alzheimer's disease. We discuss its efficacy in reducing beta-amyloid plaques, unique treatment duration protocol, and safety considerations. Could this time-limited treatment approach revolutionize how we manage Alzheimer's progression? Faculty: Scott Beach, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.75 CMEs: Quick Take Vol. 66 Can Donanemab Slow Alzheimer's Progression?
Practical psychopharmacology updates for mental health clinicians. Useful for psychiatry / mental health professionals. Expert interviews and soundbites from CME presentations. Practical and free of commercial bias. Not sponsored by any pharmaceutical company.
Brasil